Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a clinical-stage pharmaceutical company with a positive outlook on its stock due to upcoming milestones, strong enrollment rates in its CALMA trial for IGC-AD1, reported positive interim results, and a focus on developing novel therapies for Alzheimer's disease. Additionally, the company recently reported strong fiscal Q1 2026 results and has a current valuation that represents significant upside potential. Risks to achieving their $5.25 price target include balance sheet/liquidity risks and potential competition in the market.

Bears say

IGC Pharma is a clinical-stage drug development company with a focus on Alzheimer's disease. While their investigational drug assets show potential in suppressing key hallmarks of Alzheimer's, there are significant risks involved including balance sheet/liquidity concerns, failure to gain regulatory approvals, and strong competition in the market. Additionally, the company has minimal revenue and a recent change in their fiscal year could impact their financials. However, if positive data is released and the Phase 2 CALMA trial is completed successfully, there is potential for high rewards due to the large and growing market for Alzheimer's treatments.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.